Scott Galloway critiques SpaceX's IPO valuation and recommends Eli Lilly, noting both companies are involved in the GLP-1 drug market.
Steady: 0 in the last 7 days
Updated sep 16
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Scott Galloway critiques SpaceX's IPO valuation and recommends Eli Lilly, noting both companies are involved in the GLP-1 drug market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cathie Wood views SpaceX as a deep value play while Scott Galloway maintains opposing valuation views.Sub-event
- Scott Galloway warned of market shifts due to obesity and noted Eli Lilly is gaining FDA approval for weight management.Sub-event
AI IPOs are fueling demand for AI infrastructure, shifting investor focus to tech stocks.1 source
Galloway compares the valuations of Eli Lilly and SpaceX, highlighting their roles in the GLP-1 drug sector.1 source
Galloway critiques IPO market trends, citing SpaceX and Eli Lilly's performance.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
SpaceX
American private aerospace company
- SpaceX tested Rocket Cargo capabilities using a Starfall capsule carried by a Falcon 9 rideshare mission over the Pacific Ocean.
- The AI productivity market is heating up as specialized tools like Cursor, powered by OpenAI's ChatGPT and Anthropic's Claude, vie for market share alongside integrations with Microsoft and GitHub. Elon Musk's influence and SpaceX computing power are key to this race.
-
Scott Galloway
Professor of Marketing at NYU Stern School of Business, public speaker and entrepreneur
Nothing else this week.
Related events
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Goldman Sachs is the lead bank on the SpaceX IPO.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
- MarketBeat listed Eli Lilly and Company among stocks to watch on October 31, 2026.